


AMENDMENTS TO THE CLAIMS

1 – 82. (Cancelled)

83. (Previously Presented) A compound of Formula II or a pharmaceutically acceptable salt thereof:



wherein

X and Y are N,

Z is O;

Ar¹ is 2-pyridyl;Ar² is phenyl;

and wherein

at least one of the Ar¹ and Ar² moieties are substituted with one or more moieties selected from the group consisting of -F, -Cl, -Br, -I, -SR, -SOR, -SO₂R, -SO₂NRR', -OCOR, -OCONRR', -NRCOR', -NRCO₂R', -CN, -CO₂R, -CONRR', -C(O)R, -CH(OR)R', -CH₂(OR), CF₃, C₁-C₁₀ alkyl, cycloalkyl, alkyl-aryl, heterocycloalkyl, and aryl;

R and R' are independently selected from the group consisting of H, CF₃, C₁-C₁₀ alkyl, cycloalkyl, alkyl-aryl, heterocycloalkyl, aryl;

R and R' may combine to form a ring;

with the proviso that the compound is not 3-(2-Pyridyl)-5-(2-chlorophenyl)-1,2,4-oxadiazole or 3-(2-Pyridyl)-5-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole.

84. (Previously Presented) The compound according to claim 83, wherein Ar^2 is substituted with one or more moieties selected from the group consisting of CF_3 , Cl, F, Br, SCH_3 , and CN.

85. (Previously Presented) The compound according to claim 83, wherein Ar^1 is substituted with one or more moieties selected from the group consisting of CF_3 , Cl, F, Br, SCH_3 , and CN.

86. (Previously Presented) The compound according to claim 83, wherein each of Ar^1 and Ar^2 is substituted with one or more moieties selected from the group consisting of CF_3 , Cl, F, Br, SCH_3 , and CN.

87. (Currently Amended) The compound according to claim 86, wherein the compound is one selected from the group consisting of:

- 3-(5-Cyano-2-pyridyl)-5-(3-bromophenyl)-1,2,4-oxadiazole (B59),
- 3-(5-Cyano-2-pyridyl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole (B60),
- 3-(5-Cyano-2-pyridyl)-5-(3-bromo-5-fluorophenyl)-1,2,4-oxadiazole (B61),
- 3-(5-Chloropyrid-2-yl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole (B83),
- 3-(5-Chloropyrid-2-yl)-5-(3-cyano-5-chlorophenyl)-1,2,4-oxadiazole (B84),
- 3-(5-Chloropyrid-2-yl)-5-(3-chloro-5-fluorophenyl)-1,2,4-oxadiazole (B85),
- 3-(5-Fluoropyrid-2-yl)-5-(3-cyano-5-chlorophenyl)-1,2,4-oxadiazole (B87),

~~and~~ or pharmaceutically acceptable salts thereof.

88. (Currently Amended) The compound according to claim 86, wherein the compound is one selected from the group consisting of:

3-(2-pyridyl)-5-(3-chloro-5-fluorophenyl)-1,2,4-oxadiazole (B28),

3-(5-chloropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole (B29)

3-(5-fluoropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole (B30),

3-(5-fluoropyrid-2-yl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole (B31),

3-(3-fluoropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole (B32),

3-(2-pyridyl)-5-(2,5,6-trifluorophenyl)-1,2,4-oxadiazole (B45),

~~and~~ or pharmaceutically acceptable salts thereof.

89. (Canceled)

90. (Currently amended) The compound according to claim ~~89~~ 88, wherein the compound is 3-(5-fluoropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole (B30) or a pharmaceutically acceptable salt thereof.

91. (Currently amended) The compound according to claim ~~89~~ 88, wherein the compound is 3-(5-fluoropyrid-2-yl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole (B31) or a pharmaceutically acceptable salt thereof.


92. (Currently amended) The compound according to claim—~~89~~ 88, wherein the compound is 3-(3-fluoropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole (B32) or a pharmaceutically acceptable salt thereof.

93. (Currently amended) The compound according to claim—~~89~~ 87, wherein the compound is 3-(5-Cyano-2-pyridyl)-5-(3-bromophenyl)-1,2,4-oxadiazole (B59) or a pharmaceutically acceptable salt thereof.

94. (Currently amended) The compound according to claim—~~89~~ 87, wherein the compound is 3-(5-Cyano-2-pyridyl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole (B60) or a pharmaceutically acceptable salt thereof.

95. (Currently amended) The compound according to claim—~~89~~ 87, wherein the compound is 3-(5-Cyano-2-pyridyl)-5-(3-bromo-5-fluorophenyl)-1,2,4-oxadiazole (B61) or a pharmaceutically acceptable salt thereof.

96. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of Formula II or a pharmaceutically acceptable salt thereof:



wherein

X and Y are N,

Z is O;

Ar¹ is 2-pyridyl;

Ar² is phenyl;

and wherein

at least one of the Ar¹ and Ar² moieties are substituted with one or more moieties selected from the group consisting of -F, -Cl, -Br, -I, -SR, -SOR, -SO₂R, -SO₂NRR', -OCOR, -OCONRR', -NRCOR', -NRCO₂R', -CN, -CO₂R, -CONRR', -C(O)R, -CH(OR)R', -CH₂(OR), CF₃, C₁-C₁₀ alkyl, cycloalkyl, alkyl-aryl, heterocycloalkyl, and aryl;

R and R' are independently selected from the group consisting of H, CF₃, C₁-C₁₀ alkyl, cycloalkyl, alkyl-aryl, heterocycloalkyl, aryl;

R and R' may combine to form a ring;

with the proviso that the compound is not 3-(2-Pyridyl)-5-(2-chlorophenyl)-1,2,4-oxadiazole or 3-(2-Pyridyl)-5-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole.

97. (Currently Amended) The pharmaceutical composition according to claim 96, wherein the compound ~~or pharmaceutically acceptable salt thereof~~ is one selected from the group consisting of:

3-(5-fluoropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole (B30),

3-(5-fluoropyrid-2-yl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole (B31),

3-(3-fluoropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole (B32),

3-(5-Cyano-2-pyridyl)-5-(3-bromophenyl)-1,2,4-oxadiazole (B59),

3-(5-Cyano-2-pyridyl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole (B60),
3-(5-Cyano-2-pyridyl)-5-(3-bromo-5-fluorophenyl)-1,2,4-oxadiazole (B61),
and or pharmaceutically acceptable salts thereof.

98. (Previously Presented) The pharmaceutical composition according to claim 97, wherein the compound is 3-(5-fluoropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole (B30) or a pharmaceutically acceptable salt thereof.

99. (Previously Presented) The pharmaceutical composition according to claim 97, wherein the compound is 3-(5-fluoropyrid-2-yl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole (B31) or a pharmaceutically acceptable salt thereof.

100. (Previously Presented) The pharmaceutical composition according to claim 97, wherein the compound is 3-(3-fluoropyrid-2-yl)-5-(3-cyanophenyl)-1,2,4-oxadiazole (B32) or a pharmaceutically acceptable salt thereof.

101. (Previously Presented) The pharmaceutical composition according to claim 97, wherein the compound is 3-(5-Cyano-2-pyridyl)-5-(3-bromophenyl)-1,2,4-oxadiazole (B59) or a pharmaceutically acceptable salt thereof.

102. (Previously Presented) The pharmaceutical composition according to claim 97, wherein the compound is 3-(5-Cyano-2-pyridyl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole (B60) or a pharmaceutically acceptable salt thereof.

103. (Previously Presented) The pharmaceutical composition according to claim 97, wherein the compound is 3-(5-Cyano-2-pyridyl)-5-(3-bromo-5-fluorophenyl)-1,2,4-oxadiazole (B61) or a pharmaceutically acceptable salt thereof.

104. (Cancelled)

105. (Currently Amended) ~~The A method according to claim 104~~ for the treatment of a neurological disease whereby a compound according to any one of claims 83-88 or 90-95 is administered to a subject in need of such treatment.

106. (Currently Amended) ~~The A method according to claim 104~~ for the treatment of a psychiatric disease whereby a compound according to any one of claims 83-88 or 90-95 is administered to a subject in need of such treatment.

107. (Currently Amended) ~~The A method according to claim 104~~ for the treatment of a disease, wherein the disease is selected from the group consisting of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease whereby a compound

according to any one of claims 83-88 or 90-95 is administered to a subject in need of such treatment.

108. (Canceled)

109. (Cancelled)

110. (Canceled)

111. (Canceled)

112. (Canceled)

113. (Canceled)

114. (Cancelled)